BigHat Biosciences

We’re excited to share that Elizabeth Schwarzbach, CBO of BigHat Biosciences, will be participating in a panel at Tough Tech Week 2024, titled Partnering for Speed & Progress in Human Health. In this discussion, Liz will draw on her experience to highlight how partnerships are essential in driving biotech innovation. The panel will explore the vital role of collaborations between startups, venture capital, and large pharmaceutical companies in overcoming challenges such as regulatory hurdles and navigating clinical trials. Liz will be joined by industry leaders Stacy Coen, MBA (CBO, ImmunoGen, Inc.) and Rachel Sha (CEO, Vaxess Technologies) on the panel, which will be moderated by Ann DeWitt, General Partner at Engine Ventures. 💡 Panel Discussion: Partnering for Speed & Progress in Human Health 🗓 October 08 | 2:00 P.M. ET 📍 Location: Tough Tech Week 2024 [Boston/Cambridge, MA] https://toughtechweek.xyz/

We’re thrilled to announce that Charbel Eid, VP of Platform at BigHat Biosciences, will be giving an invited talk at the upcoming LRIG Bay Area Chapter event! Charbel will be sharing insights into how BigHat is revolutionizing the development of next-generation antibody therapeutics through AI-guided design. He’ll dive into the power of BigHat’s Milliner™ platform, which integrates a cutting-edge, high-speed wet lab with AI/ML to accelerate antibody discovery and optimization. To register: https://lnkd.in/gQhGTHJi #LRIG #BigHatBiosciences #AI #Biotech #AntibodyEngineering

We welcome Diana, Rima and Helena! Diana David joins us as Executive Administrator to BigHat’s Corporate Dev & Ops team. Diana will support BigHat’s Leadership, Business Development, and Recruiting related administrative activities. After over two years of incredible work with us via Persona, we’re thrilled to officially have her on board. She's passionate about growth and learning and is currently pursuing her MBA at Don Honorio Ventura Technological State University. Rima Sanyal joins us as Associate Scientist, Translational Research. Rima will be performing and developing immunological assays to support our internal programs pipeline. Rima has a wealth of experience in immunology, with a background in T cell biology, biochemistry and CAR-T therapy manufacturing. Prior to joining BigHat, she assisted in the discovery and deorphanization of T cell receptors to advance diagnostic and therapeutic efforts for cancer and autoimmune diseases at Adaptive Biotechnologies Corp. Rima holds a B.S. in Biochemistry and Molecular Biology from Chapman University. Helena Fu joins us as Research Associate II, Translational Research. At BigHat, Helena will lead various in vitro studies and antibody engineering efforts at BigHat, supporting our internal programs. Helena graduated from the University of California, Santa Cruz with a degree in Molecular, Cell & Developmental Biology. Previously she was at Twist Bioscience, where she was involved in antibody discovery efforts. She has experience in kinetics, phage display, and antibody engineering. Welcome to the team, Diana, Helena and Rima! https://lnkd.in/grt3Vjx9

🌟 A BIG Thank You! Peyton Greenside Summits Kilimanjaro for Sickle Forward! 🏔️🎉 We are thrilled to announce that BigHat’s Cofounder and CSO, Peyton Greenside has successfully completed the Timmerman Traverse, summiting Mt. Kilimanjaro along with 20 other team members to raise funds for Sickle Cell Disease (SCD) in sub-Saharan Africa! 🌍 Thanks to your support, we not only reached but exceeded our $50,000 goal, contributing to over $2 million total to bring newborn screening and treatment to those in need. We are also excited to share that BigHat’s work continues with a next-gen antibody for treating and preventing SCD vaso-occlusive crises in preclinical development. Stay tuned for more updates on our program. A huge thank you to all who donated, Luke Timmerman, the Timmerman Report Traverse and Sickle Forward teams for their dedication and leadership in making this effort possible! Thank you again to everyone who supported Peyton and the Timmerman Traverse team!  #TimmermanTraverse #SickleForward

We welcome Sayantan Mitra, Ph.D., Isabella Bangs and Tim Randle! Sayantan Mitra, Ph.D. joins us as Director, Protein Sciences. Sayantan will be focusing on scaling BigHat’s Protein Sciences team and setting an ambitious technical roadmap supporting the mission of advancing BigHat’s state-of-the-art antibody engineering platform and therapeutic pipeline. Sayantan is a protein engineer with a deep passion for helping discover and develop novel therapeutic treatments for cancer and autoimmune diseases. He has over 16 years of experience in peptide chemistry, protein and antibody engineering, therapeutic antibody discovery, cytokine engineering and cell therapy. He has been a key contributor to several different modalities in clinical development such as monoclonal antibodies, conditionally active bispecific antibodies and engineered cytokines. Prior to joining BigHat, Sayantan led the Protein Sciences team at Metagenomi developing innovative ex-vivo cell therapies. Sayantan holds a PhD in Chemical Biology from the University of Southern California and conducted Postdoctoral Research in Cell Biology at Sanford Burnham Prebys Medical Discovery Institute. Isabella Bangs joins as Lab Operations Associate. Isabella will further enhance our ability to support all aspects of lab activity as well as help scale lab operations. Isabella received a BS in Botany from Cal Poly Humboldt, where she specialized in plant cell culture and plant physiology. Prior to BigHat, she spent two years at Green Diamond Resource Company's clonal Sequoia sempervirens laboratory, aiding the Silviculture department in reforestation of Northern California. Her focus was improving recovery protocols for contaminated culture and improving drought-tolerant phenotypes. Tim Randle joins BigHat as Director, Development Program Management.  As the program management lead for the development organization, he will play a pivotal role in organizing and structuring the Development team at BigHat, leading strategic initiatives for the Development organization, and driving the advancement of our biologics pipeline from discovery through clinical development. Tim is an accomplished program management leader with over 20 years of experience in program management and operations development encompassing enzyme replacement therapies, neuromodulators, and cytokine antagonists. Prior to joining BigHat, Tim led drug development project and program management teams for Alpine Immune Sciences, Inc., Codexis, Inc. and Revance as well as process and operations development and management for Revance and BioMarin Pharmaceutical Inc. Tim’s range of experience spans all clinical phases through launch and commercialization. Welcome to the BigHat team, Sayantan, Isabella and Tim! https://lnkd.in/grt3Vjx9

Elizabeth Schwarzbach, CBO of BigHat, will join Atomic AI, Compass Pathways, ZS and DeepCure for a panel discussion: “Maximizing Returns: Unleashing the Power of AI for Tangible ROI” at the 7th LSX - partnering for Life Science eXecutives 2024 on September 11, 2024 3:50 pm EST. https://lnkd.in/gNZyzdqz 

We welcome Anisha Keshavan, Crystal H. and Vanessa Le! Anisha joins us as a Senior Data Scientist II. Anisha will be focusing on supercharging data analysis and visualization in our proprietary LIMS, Reccy. Anisha earned her BS in Aerospace Engineering and Applied Math at UCLA and her PhD in Bioengineering at University of California, San Francisco + University of California, Berkeley. She previously served as Lead Data Scientist at Octave and has extensive experience in data visualization, data-focused app development, and computer vision. Crystal joins as Principal Data Scientist. Crystal will develop a data science strategy focused on evaluating and refining the ML-driven antibody design methods deployed on our platform, and aligning the scaling of data generation and processing with improved model performance and therapeutic program advancement. Crystal is a PhD researcher with over a decade of experience spanning human genomics, experimental design, optimization, and statistical modeling. She has led projects at Amazon, Zymergen, and Google [X, the moonshot factory]. Vanessa Le joins BigHat as an Associate Software Engineer II. Vanessa will be working on tools to accelerate how we design and track antibodies through Reccy as well as improve ways in which we capture experimental data. Vanessa is a recent graduate from Northeastern University with a degree in Computer Science. She completed a software engineering co-op at BigHat before coming back to work with the team as a full-time employee. She is passionate about computer science due to its problem-solving nature and loves being able to see the positive impact that her work brings to people's lives. Welcome to the BigHat team, Anisha, Crystal and Vanessa! https://lnkd.in/grt3Vjx9  

Peyton Greenside, our Co-founder and CSO, is training with the BigHat team as she prepares for the Timmerman Traverse for Sickle Forward this September. She’ll be climbing Mt. Kilimanjaro to help raise awareness and funds for sickle cell disease treatment in sub-Saharan Africa. We’re proud to support her in this important mission. Only 4 days left to support! https://lnkd.in/g6PyYPJt #TimmermanTraverse #SickleForward #BigHat #SCD #MtKilimanjaro

We’re excited to share that BigHat Biosciences was featured in Genetic Engineering & Biotechnology News. Our co-founder and CSO, Peyton Greenside, discussed how AI is advancing traditional antibody engineering by leveraging diverse antibody sequences, modeling multiple properties simultaneously, and generating novel antibodies to meet unmet medical needs. To read full article: https://lnkd.in/dRUcbggP 

🚀 Exciting News! 🚀 We are thrilled to announce that BigHat Biosciences has been featured on 2024’s Fierce Biotech 15! This prestigious recognition highlights our fierce approach in leveraging machine learning and synthetic biology for high quality antibody drug discovery. A huge shoutout to our dedicated team and partners who make this possible! Together, we're pushing the boundaries of biotech and making strides towards better treatments for patients worldwide. 🌍 Check out the full article to learn more about our journey and vision: https://lnkd.in/gUgbkwhw